Multidisciplinary management of type 2 inflammatory diseases

Area of Science:

• Immunology and Molecular Medicine
• Dermatology, Pulmonology, and Otolaryngology

Background:

• Excessive type 2 inflammation underlies atopic dermatitis (AD), asthma, and chronic rhinosinusitis with nasal polyps (CRSwNP).
• Glucocorticoids are standard but have adverse effects and limitations for chronic type 2 inflammatory diseases.
• Targeted biologics, like dupilumab, offer new therapeutic avenues by inhibiting key inflammatory pathways.

Purpose of the Study:

• To overview AD, asthma, and CRSwNP, highlighting their shared type 2 inflammatory basis.
• To present practical guidance for a multidisciplinary management approach to these conditions.
• To emphasize the role of novel biological agents in managing type 2 inflammatory diseases.

Main Methods:

• Review of current understanding of type 2 inflammation in AD, asthma, and CRSwNP.
• Discussion of the limitations of traditional therapies (glucocorticoids).
• Introduction of targeted biological therapies, exemplified by dupilumab.
• Proposal of a multidisciplinary team model involving dermatology, pulmonology/allergology, and ENT specialists.

Main Results:

• Type 2 inflammation is a common pathogenic mechanism in AD, asthma, and CRSwNP.
• Dupilumab is an approved targeted therapy for these conditions, addressing limitations of steroids.
• A multidisciplinary approach is proposed to optimize patient care and decision-making.

Conclusions:

• A structured, flexible multidisciplinary team is essential for optimal management of type 2 inflammatory conditions.
• Novel biological agents like dupilumab represent a significant advancement in treating these diseases.
• Integrated care models improve outcomes, reduce costs, and enhance patient management for chronic inflammatory diseases.